MOREPEN

Date: 12/02/2021

To,

National Stock Exchange of India Ltd. BSE Limited Exchange Plaza, Bandra Kurla Complex, Floor 25, Phiroze Jeejeebhoy Towers, Bandra (East), Mumbai- 400 051 Dalal Street, Mumbai- 400 001 Symbol: MOREPENLAB Scrip Code: 500288

Subject: Investors Presentation (Q3'°F Y21) February 2021

Dear Sir,

Please find enclosed the Investors Presentation (Q3'F Y21) February 2021, based on the financial performance of the Company for the Quarter and Nine months ended 31* ' December, 2020.

Kindly acknowledge the receipt and take it on your record.

Thanking you.

Yours faithfully,

(Vipul Kumar Srivastava) Company Secretary

Encl.: As Above

Corp. Off.: 4th Floor,Antriksh Bhawan, 22 K.G.Marg, New Delhi- 110 001, INDIA Tel.:+91-11-23324443, 23712025, E-mail: [email protected],Website:www.morepen.com CIN NO. L24231 HP1984PLC006028

MOREPEN

Q3'FY21

(Investor Presentation February 2021)

Disclaimer/ Confidentiality:

This presentation has been prepared by Morepen Laboratories Limited ("Company") solely for information purposes without regard to any specific objectives, financial situations or informational needs of any particular person. This presentation contains expressed or implied forward looking statements, including discussions of our future plans, strategy, research and deployment activities and products in pipeline. Such forward looking statements reflect current views of the Company or its subsidiaries regarding future events, and involve known or unknown risks, uncertainties and other factors that may cause actual results to be different from any future results expressed or implied by such statements.

This presentation has been prepared by the Company based on information an data which the Company considers reliable, but the Company makes ho representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and a reasonableness of the contents of this presentation. All actions and statements made herein or otherwise shall be subject to the applicable laws | and regulations as amended from time to time. This presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this presentation is expressly excluded. The Company is providing the information in this presentation as of date and does not undertake any obligation as to the regular updating of the information as aresult of new information, future events or otherwise.

G 2 om zi The contents of this presentation are confidential and should not be distributed, published or reproduced, in whole or part, or disclosed by es ps ttn —_ recipients, either directly or indirectly, to any other person. It is advised that prior to acting upon this presentation independent consultation / DO yeariof advice may be obtained and necessary due diligence, investigations, etc. may be conducted at the end of the recipient.

This presentation does not constitute or form part of and should not be construed, either directly or indirectly, as any offer or invitation or — _ < inducement to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities of the Company by any person in any jurisdiction. This presentation is not a prospectus, a statement in lieu of a prospectus, an offering circular, an advertisement or an offer document under the Companies Act, 2013, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009, as amended, or any other applicable law in India.

This presentation contain confidential data and information about the company historical performance and future business plan strategy and the any reader/user can not copy, circuculate or use disclose the said information or part of it to anyone without prior written permission of the Company. Any unauthorised use of the data will attract legal action against the person.

HIGHLIGHTS FOR THE QUARTER

$CO$

Rs. in crores Q3'FY21

Exponential growth

Subsidiary

BULK DRUGS (API)

Strong portfolio of lifestyle drugs including antidiabetics, antihypertensives, neuropsychiatric, anticancers and anti-virals

DIAGNOSTIC DEVICES

Home diagnostics including glucose meters, BP monitors, nebulisers, weighing scales, digital and IR thermometers, Oximeters, Oxygen Concentrators

FINISHED DOSAGES

Prescription drugs development, manufacturing, distribution, contract manufacturing, marketing all over India both as branded and generic drugs

MANUFACTURING FACILITES

Global Approvals/ International Standards

APIs, R&D, Diagnostic Devices, Formulation, OTC

Baddi (HP)

APIs, R&D

Masulkhana (HP)

Formulation

Parwanoo (HP)

SEGMENT WISE GROWTH

. API and Devices grow exponentially

$CO$

Rs. in crores Q3'FY21

INTELLECTUAL PROPERTY

The Growth Engine

API EXPANSION PROJECT

Major Expansion after 22 years

Govt. folndia supporting API expansions plans and has also launched performance linked incentive scheme

Make India

$178...$ Project Cost

Completion time

$MT$ Capacity

New Products

$\overline{D}$

New

Production Value

New Section

Project Site-

EXPANDING API MARKET

New Molecules add 15X market size

_ \Piotal global market size of the all the products , ante the Company is presently sellingis only USD Billion \$4.004 Bil and in. coming five years is goingto . 40 go down to s2}g35Mion since these are all old products for which patent expired in last 10-20 years ago and the make is not expanding very 35.937 fast though Company is growing at 27% CAGR 30

With addiction of New Molecules foe which patent expiry is slated in 5-6 years, anew market of \$35.937 Billion opens up which will grow to ~ ugll 20